Cargando…

The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer

Detalles Bibliográficos
Autor principal:	Aragon-Ching, Jeanny B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Invited Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831828/ https://www.ncbi.nlm.nih.gov/pubmed/32719192 http://dx.doi.org/10.4103/aja.aja_35_20

Ejemplares similares

Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
por: Aragon-Ching, Jeanny B
Publicado: (2016)

The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2016)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

ARASENS: making sense out of first-line metastatic hormone-sensitive prostate cancer treatment
por: Aragon-Ching, Jeanny B
Publicado: (2022)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

Prostate cancer screening: and yet it moves!
por: Kwiatkowski, Maciej, et al.
Publicado: (2015)

Vitamin D in prostate cancer
por: Trump, Donald L, et al.
Publicado: (2018)

The path forward in prostate cancer therapeutics
por: Aragon-Ching, Jeanny B, et al.
Publicado: (2018)

Role of chemotherapy in prostate cancer
por: Nader, Rita, et al.
Publicado: (2018)

Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
por: Rhea, Logan P, et al.
Publicado: (2019)

Robotic radical prostatectomy in high-risk prostate cancer: current perspectives
por: Canda, Abdullah Erdem, et al.
Publicado: (2015)

Testosterone replacement therapy and the risk of prostate cancer
por: Warburton, Daniel, et al.
Publicado: (2015)

HOXB13 and other high penetrant genes for prostate cancer
por: Pilie, Patrick G, et al.
Publicado: (2016)

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
por: Combes, Alexander D., et al.
Publicado: (2022)

Prostate-specific membrane antigen (PSMA)–ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer
por: Tateishi, Ukihide
Publicado: (2020)

The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer
por: Erdoğan, Mehmet, et al.
Publicado: (2020)

To screen or not to screen: the prostate cancer dilemma
por: Stone, Nelson N, et al.
Publicado: (2015)

Irreversible electroporation for prostate cancer using PSMA PET-CT
por: Shin, Dongho, et al.
Publicado: (2023)

External beam radiotherapy for localized prostate cancer
por: Yilmaz, Hasan, et al.
Publicado: (2015)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Current and emerging trends in prostate cancer immunotherapy
por: Schatz, Adam, et al.
Publicado: (2019)

The value of (18)F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer
por: Hong, Jun-jie, et al.
Publicado: (2020)

(68)Ga-PSMA PET-CT and PSMA score affecting therapeutic decision-making in high-risk prostatic carcinoma
por: Yasmin, Tahira, et al.
Publicado: (2023)

PSMA PET in Imaging Prostate Cancer
por: Tsechelidis, Ioannis, et al.
Publicado: (2022)

Androgen receptor functions in prostate cancer development and progression
por: Balk, Steven P
Publicado: (2014)

Prevention of erectile dysfunction after radiotherapy for prostate cancer
por: Faiena, Izak, et al.
Publicado: (2014)

Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer
por: Cereser, Lorenzo, et al.
Publicado: (2023)

Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with (68)Ga-PSMA PET/CT Features in Primary Staging
por: Vetrone, Luigia, et al.
Publicado: (2023)

PSMA-targeted imaging of prostate cancer: evolution of a success story
por: Maurer, Tobias, et al.
Publicado: (2017)

Next generation patient-derived prostate cancer xenograft models
por: Lin, Dong, et al.
Publicado: (2014)

Long-term survival of participants in the prostate cancer prevention trial
por: Silberstein, Jonathan L, et al.
Publicado: (2014)

Management of localized prostate cancer: the pendulum swings (back to the middle)
por: Vuong, Winston, et al.
Publicado: (2014)

Lipogenic metabolism: a viable target for prostate cancer treatment?
por: Liang, Mengmeng, et al.
Publicado: (2014)

Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity
por: Mendonca, Janet, et al.
Publicado: (2015)

The management impact of (68)gallium-tris(hydroxypyridinone) prostate-specific membrane antigen ((68)Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer
por: Kulkarni, Meghana, et al.
Publicado: (2019)

PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?
por: Urso, Luca, et al.
Publicado: (2023)

PSMA-PET in the early stages of prostate cancer
por: Barbosa, Felipe de Galiza
Publicado: (2023)

Re: Long-term survival of participants in the Prostate Cancer Prevention Trial
por: Thompson, Ian M, et al.
Publicado: (2014)

Long noncoding RNA-mediated activation of androgen receptor in prostate cancer
por: Petrovics, Gyorgy, et al.
Publicado: (2014)

Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification
por: Chiang, Yan Ting, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nbktf8ke4sb590616qppobdu92